Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaniaga BhdXKLS:7081 +1.72%45 PE Ratio without NRI is 20.70 as of Jul. 31, 2026, which is 30% above its 10-year median of 15.98. GuruFocus rates XKLS:7081 with a GF Score™ of 45/100 and a GF Value™ of RM0.71 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 87 Medical Distribution companies, Pharmaniaga Bhd ranks worse than 73.56% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-31), Pharmaniaga Bhd's share price is RM1.18.
Pharmaniaga Bhd's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was RM0.06. Therefore, Pharmaniaga Bhd's PE Ratio without NRI for today is 20.70.
During the past 13 years, Pharmaniaga Bhd's highest PE Ratio without NRI was 50.34. The lowest was 2.34. And the median was 15.98.
During the past years, Pharmaniaga Bhd's highestPE Ratio (TTM) was 50.34. The lowest was 2.34. And the median was 15.98.
Pharmaniaga Bhd's
EPS (Diluted) for the
three
months ended in Mar. 2026 was RM0.02.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was RM0.06.
Pharmaniaga Bhd's EPS (Basic) for the
three
months ended in Mar. 2026 was RM0.02.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was RM0.06.
Pharmaniaga Bhd (XKLS:7081) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Pharmaniaga Bhd PE Ratio without NRI Related Terms
Pharmaniaga Bhd PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for Pharmaniaga Bhd's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7081 vs MCK, COR, CAH: PE Ratio without NRI Comparison
For the Medical Distribution subindustry, Pharmaniaga Bhd's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaniaga Bhd PE Ratio without NRI vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Pharmaniaga Bhd's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Pharmaniaga Bhd's PE Ratio without NRI falls into.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Pharmaniaga Bhd's PE Ratio without NRI for today is calculated as
Pharmaniaga Bhd's Share Price of today is RM1.18.
Pharmaniaga Bhd's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Pharmaniaga Bhd (XKLS:7081) has a PE Ratio without NRI of 20.70 as of Jul. 31, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Pharmaniaga Bhd and its competitors. This is 30% above median its historical median of 15.98. Over the past decade, Pharmaniaga Bhd's PE Ratio without NRI has ranged from 2.34 to 50.34. According to the industry distribution chart, Pharmaniaga Bhd ranks #64 out of 87 companies in the Medical Distribution industry, placing it in the top 73.6%.
Is Pharmaniaga Bhd's PE Ratio without NRI too high?
Pharmaniaga Bhd's current PE Ratio without NRI of 20.70 is 30% above median its 10-year median of 15.98. Over the past 10 years, this metric has ranged from a low of 2.34 to a high of 50.34. The Medical Distribution industry median PE Ratio without NRI is 15.39. Pharmaniaga Bhd's value of 20.70 is 34.5% above this industry median. Based on the distribution chart, Pharmaniaga Bhd ranks #64 out of 87 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Pharmaniaga Bhd has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaniaga Bhd's PE Ratio without NRI compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Pharmaniaga Bhd ranks #64 out of 87 companies for PE Ratio without NRI. This places Pharmaniaga Bhd in the lower half of its industry. The industry median PE Ratio without NRI is 15.39. Pharmaniaga Bhd's value of 20.70 is 34.5% above this benchmark. Historically, Pharmaniaga Bhd's own PE Ratio without NRI has ranged from 2.34 to 50.34 over the past decade. While the company's 10-year median is 15.98 vs. the industry median of 15.39, Pharmaniaga Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Distribution company?
The median PE Ratio without NRI among Medical Distribution companies is 15.39, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaniaga Bhd's current PE Ratio without NRI of 20.70 is 34.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Pharmaniaga Bhd and its competitors. For the Medical Distribution industry, the median PE Ratio without NRI is 15.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaniaga Bhd's current PE Ratio without NRI is 20.70, which is 30% above median its own 10-year median of 15.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaniaga Bhd stock overvalued right now?
Based on GuruFocus' analysis, Pharmaniaga Bhd (XKLS:7081) is currently considered Significantly Overvalued. The stock's GF Value™ is RM0.71, compared to a current price of RM1.18 — trading 66.2% above its estimated fair value. The current PE Ratio without NRI is 20.70, which is 30% above median its 10-year median of 15.98 and 34.5% above the Medical Distribution industry median of 15.39. Pharmaniaga Bhd's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Pharmaniaga Bhd (XKLS:7081), the current PE Ratio without NRI is 20.70 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaniaga Bhd (XKLS:7081) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaniaga Bhd stock appears to be overvalued.
The current stock price of RM1.18 is trading 66.2% above its estimated GF Value™ of RM0.71.
GuruFocus considers Pharmaniaga Bhd to be Significantly Overvalued.
Key valuation signals for XKLS:7081:
PE Ratio without NRI: 20.70 (30% above median its 10-year median of 15.98)
GF Value™: RM0.71 vs. price of RM1.18 (66.2% above fair value)
Industry Position: 34.5% above the Medical Distribution median (#64 of 87)
No single metric tells the full story. See the XKLS:7081 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaniaga Bhd is engaged in the manufacture of pharmaceuticals and medical devices. The company is also involved in logistics and distribution. The group operates in three segments - Logistics and distribution, Manufacturing in Malaysia, and Manufacturing and distribution in Indonesia. Maximum revenue is generated by the logistics and distribution segment in Malaysia. The Logistics and distribution segment is engaged in distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia.
45GF Score
Get the complete analysis for XKLS:7081
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7081 has been successfully added to your 
